Parkinson disease research advances in biomarkers and neuromodulation

Recent research and clinical discussions are highlighting advancements in the diagnosis and management of Parkinson disease (PD). A study published in BMJ Neurology Open evaluated the diagnostic utility of dopamine transporter single-photon emission CT (DaT SPECT) imaging and phosphorylated alpha-synuclein (p-Syn) skin biopsies for identifying synucleinopathies.

The study found that while both tests showed similar sensitivity (79.0%), combining them increased sensitivity to 95.6% but reduced specificity to 59.9%. Discordant results occurred in 30.8% of dual-tested patients, with different clinical symptoms, such as hyposmia or REM sleep behavior disorder, correlating with specific test outcomes.

In parallel, experts at the 2026 International Congress of Parkinson’s Disease and Movement Disorders are focusing on the evolving roles of biomarkers, genetic characterization, and adaptive deep brain stimulation (DBS). These developments aim to improve early identification and personalized care, though the development of effective disease-modifying therapies remains a primary challenge in the field.